Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Vanda Pharmaceuticals Inc (VNDA) Financials: Revenue, Profit and Cash Flow
Vanda Pharmaceuticals reported revenue of $216.10M for the fiscal year ended Dec 31, 2025, up 8.7% from the year before. That year, net income was -$220.47M with a net margin of -102.0%, operating cash flow was -$109.44M and free cash flow was -$110.44M. The quarter ended Sep 30, 2026 had revenue of $69.81M and net income of -$22.56M.
Revenue and Margins
The operating margin was -70.0% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $146.02M, a compound annual rate of 4.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $216.10M | +8.7% | 94.0% | -70.0% | -102.0% |
| Dec 2024 | $198.77M | +3.2% | 94.3% | -20.5% | -9.5% |
| Dec 2023 | $192.64M | -24.3% | 92.3% | -7.2% | 1.3% |
| Dec 2022 | $254.38M | -5.3% | 90.5% | 2.5% | 2.5% |
| Dec 2021 | $268.68M | +8.3% | 90.5% | 15.7% | 12.3% |
| Dec 2020 | $248.17M | +9.2% | 90.6% | 11.0% | 9.4% |
| Dec 2019 | $227.19M | +17.6% | 89.2% | 10.0% | 50.9% |
| Dec 2018 | $193.12M | +17.0% | 89.4% | 11.3% | 13.1% |
| Dec 2017 | $165.08M | +13.1% | 89.2% | -10.2% | -9.4% |
| Dec 2016 | $146.02M | N/A | 83.1% | -12.7% | -12.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.10M | $198.77M | $192.64M | $254.38M | $268.68M | $248.17M | $227.19M | $193.12M | $165.08M | $146.02M |
| Cost of revenue | $13.04M | $11.31M | $14.80M | $24.28M | $25.63M | $23.36M | $24.49M | $20.51M | $17.85M | $24.71M |
| Gross profit | $203.06M | $187.46M | $177.84M | $230.10M | $243.05M | $224.80M | $202.70M | $172.61M | $147.24M | $121.31M |
| Research and development | $109.27M | $74.43M | $76.82M | $85.77M | $75.36M | $55.58M | $48.65M | $43.59M | $38.55M | $29.16M |
| Operating income | -$151.17M | -$40.66M | -$13.95M | $6.33M | $42.16M | $27.24M | $22.81M | $21.74M | -$16.90M | -$18.57M |
| Net income | -$220.47M | -$18.90M | $2.51M | $6.28M | $33.15M | $23.34M | $115.55M | $25.21M | -$15.57M | -$18.01M |
| EBITDA | -$128.78M | -$20.12M | $1.87M | $11.07M | $46.85M | $34.70M | $28.82M | $26.08M | -$12.87M | -$6.01M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.81M | $50.53M | $51.72M | $57.22M | $56.26M | $52.59M | $50.04M | $53.19M | $47.65M | $50.47M | $47.46M | $45.27M |
| Gross profit | $65.66M | $46.97M | $48.56M | $53.38M | $53.30M | $49.85M | $46.52M | $50.59M | $45.10M | $47.74M | $44.02M | $41.81M |
| Operating income | -$23.52M | -$63.81M | -$50.22M | -$40.35M | -$31.28M | -$38.50M | -$41.03M | -$10.28M | -$11.00M | -$10.15M | -$9.23M | -$7.09M |
| Net income | -$22.56M | -$62.51M | -$48.57M | -$141.19M | -$22.59M | -$27.21M | -$29.49M | -$4.91M | -$5.32M | -$4.52M | -$4.15M | -$2.40M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $5.55M by $79.30M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $488.95M | $656.20M | $648.44M | $634.25M | $593.79M | $533.46M | $483.75M | $332.13M | $205.43M | $210.37M |
| Current assets | $347.26M | $438.89M | $432.95M | $519.29M | $478.30M | $409.14M | $354.14M | $299.13M | $169.86M | $174.18M |
| Cash and equivalents | $84.85M | $102.32M | $135.82M | $135.03M | $52.07M | $61.03M | $45.07M | $61.01M | $33.63M | $40.43M |
| Total liabilities | $161.76M | $117.66M | $103.53M | $107.05M | $88.86M | $80.19M | $72.80M | $56.71M | $74.04M | $79.04M |
| Short-term debt | $5.55M | $4.27M | $2.40M | $2.33M | $2.31M | $2.12M | $2.15M | N/A | $27.00M | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $25.00M |
| Shareholder equity | $327.19M | $538.55M | $544.91M | $527.20M | $504.93M | $453.27M | $410.94M | $275.42M | $131.39M | $131.33M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $382.33M | $412.47M | $433.52M | $488.95M | $601.14M | $624.75M | $631.94M | $656.20M | $645.12M | $651.37M | $652.68M | $648.44M |
| Total liabilities | $182.47M | $192.28M | $152.76M | $161.76M | $135.14M | $138.42M | $120.52M | $117.66M | $103.89M | $108.86M | $108.69M | $103.53M |
| Cash and equivalents | $61.93M | $55.88M | $54.03M | $84.85M | $70.02M | $80.98M | $111.80M | $102.32M | $100.50M | $102.95M | $125.16M | $135.82M |
| Shareholder equity | $199.86M | $220.19M | $280.76M | $327.19M | $466.00M | $486.33M | $511.42M | $538.55M | $541.22M | $542.52M | $544.00M | $544.91M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$109.44M | -$15.76M | $12.80M | $31.98M | $64.21M | $51.77M | $45.95M | $29.99M | -$1.98M | -$8.10M |
| Capital expenditures | $998.00K | $490.00K | $383.00K | $679.00K | $552.00K | $1.79M | $1.02M | $368.00K | $1.66M | $1.41M |
| Free cash flow | -$110.44M | -$16.25M | $12.42M | $31.30M | $63.66M | $49.98M | $44.93M | $29.62M | -$3.65M | -$9.51M |
| Investing cash flow | $94.86M | -$17.43M | -$12.06M | $49.92M | -$76.70M | -$41.50M | -$68.31M | -$109.66M | -$10.23M | -$10.03M |
| Financing cash flow | -$2.91M | -$155.00K | $0 | $734.00K | $3.55M | $5.63M | $6.26M | $107.13M | $5.25M | $7.75M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.43M | -$31.07M | -$50.22M | -$29.42M | -$31.63M | -$15.25M | -$33.15M | -$1.82M | -$14.58M | -$6.93M | $7.57M | -$3.73M |
| Capital expenditures | $311.00K | $190.00K | $221.00K | $102.00K | $161.00K | $299.00K | $436.00K | $214.00K | $161.00K | $108.00K | $7.00K | $253.00K |
| Free cash flow | -$28.75M | -$31.26M | -$50.44M | -$29.52M | -$31.79M | -$15.55M | -$33.58M | -$2.03M | -$14.74M | -$7.04M | $7.56M | -$3.98M |
Frequently Asked Questions About VNDA
What is Vanda Pharmaceuticals' annual revenue?
Vanda Pharmaceuticals reported revenue of $216.10M for the fiscal year ended Dec 31, 2025.
How fast is Vanda Pharmaceuticals' revenue growing?
Revenue was up 8.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.3%.
Is Vanda Pharmaceuticals profitable?
No. Vanda Pharmaceuticals reported net income of -$220.47M for the fiscal year ended Dec 31, 2025, with a net margin of -102.0%.
How much free cash flow does VNDA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$109.44M minus capital expenditures of $998.00K produced free cash flow of -$110.44M.
How much debt does Vanda Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.55M and cash and equivalents of $84.85M.
VNDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts